This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01411/identifier/pharmgkb/
n18http://linked.opendata.cz/resource/mesh/concept/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01411/identifier/pubchem-compound/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01411/identifier/pubchem-substance/
n16http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB01411/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n14http://linked.opendata.cz/resource/drugbank/drug/DB01411/identifier/chemspider/
n17http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01411/identifier/wikipedia/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01411
rdf:type
n3:Drug
n3:description
Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
n3:generalReferences
# Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S: Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma. Drug Metab Pharmacokinet. 2006 Apr;21(2):133-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16702733
n3:group
approved
n3:indication
Used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists.
owl:sameAs
n8:DB01411 n16:DB01411
dcterms:title
Pranlukast
adms:identifier
n6:PA134698661 n12:46508129 n13:115100 n14:102999 n15:DB01411 n19:Pranlukast
n3:mechanismOfAction
Pranlukast selectively antagonizes leukotriene D<sub>4</sub> (LTD<sub>4</sub>) at the cysteinyl leukotriene receptor, CysLT<sub>1</sub>, in the human airway. Pranlukast inhibits the actions of LTD<sub>4</sub> at the CysLT<sub>1</sub> receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.
n3:synonym
ONO-RS 411 SID50126316
n3:toxicity
Side effects include headache, abdominal or stomach pain, cough, dental pain, dizziness, fever, heartburn, skin rash, stuffy nose, weakness or unusual tiredness.
n3:synthesisReference
Seiei Sasatani, Masashi Shiota, Yoshinori Ii, "Granules containing pranlukast, process for producing the granules, and method of improving adhesiveness of pranlukast." U.S. Patent US5876760, issued March, 1995.
n17:hasConcept
n18:M0137595
n3:IUPAC-Name
n4:271B479A-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B47A0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B479F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B479C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B479D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B479E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4798-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4796-363D-11E5-9242-09173F13E4C5 n4:271B4799-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4797-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:R03DC02
n3:H-Bond-Acceptor-Count
n4:271B47A6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B47A7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B47A1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B47A2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B47A4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B47A3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B47A5-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
103177-37-3
n3:category
n3:Bioavailability
n4:271B47AC-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B47AE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B47AF-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B47AB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B47AA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B47AD-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B479B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B47A8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B47A9-363D-11E5-9242-09173F13E4C5